RxDoctor Payments Data

Kristen Brooks, NP

Family · Greenville, SCNPI 1396262820

Payments from drug & device makers

$2,613in general payments, 2019–2025

Across 44 payments — averaging $59.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$280
  • Endo USA, Inc.$182
  • Bayer$125
  • Teleflex LLC$121
  • 180 Medical, Inc.$108
  • plus $295 from 7 others

What the payments were for

  • Travel & lodging$90635%
  • Food & beverage$1,70765%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic22$1,503
Boston Scientific2$280
Endo USA, Inc.3$182
Bayer1$125
Teleflex LLC1$121
180 Medical, Inc.4$108
Coloplast4$97
EDAP Technomed Inc1$65
Johnson & Johnson1$39
Astellas Pharma US Inc2$38
Tolmar Pharmaceuticals, Inc.1$19
ABC Home Medical Supply, Inc.1$19
Urovant Sciences Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,613 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$43,045
Medicare patients
309
Services billed
2,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron77$43,212
GemtesaVibegron33$23,249
Estradiol86$4,885
Methenamine Hippurate21$2,204
Tamsulosin Hcl76$1,019
Finasteride46$478
Solifenacin Succinate21$414
Oxybutynin Chloride ErOxybutynin Chloride17$366
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$243
Ciprofloxacin Hcl40$122
Cephalexin18$46
Amitriptyline Hcl12$31
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$38$43,21277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →